{ "items": [ "\n\n
\n \n\n \n \n \n \n OUCRU\n \n \n\n \n\n\n
\n \n\n \n26 August 2020
\n \n \n \nThe World Mosquito Program posted the results of a 3-year randomised controlled trial in Yogyakarta, Indonedia, providing compelling gold standard evidence for the efficacy of the Wolbachia method in controlling dengue. The deployment of Wolbachia-carrying Aedes aegypti mosquitoes lead to a reduction of 77% in dengue incidence in Wolbachia-treated versus untreated areas.
\n \n\n \n \n\n \n\n \n \n \n \n MORU\n \n \n\n \n\n\n
\n \n\n \n6 August 2020
\n \n \n \nHydroxychloroquine could still prevent COVID-19 and save tens of thousands of lives around the world, say leading scientific researchers. While it doesn\u2019t work in treatment of hospitalised patients, it could still prevent infections. However, fraudulent data, unjustified extrapolation and exaggerated safety concerns together with intense politicisation and negative publicity may stop COPCOV, the only large, global clinical trial testing hydroxychloroquine in COVID-19 prevention, from ever finding out.
\n \n\n \n \n\n \n\n \n \n \n \n NDM-CGHR\n \n \n\n \n\n\n
\n \n\n \n21 July 2020
\n \n \n \nA team of scientists at Oxford University\u2019s Jenner Institute and Oxford Vaccine Group has taken the next step towards the discovery of a safe, effective and accessible vaccine against coronavirus. The results of the Phase I/II trial published in The Lancet indicate no early safety concerns and induces strong immune responses in both parts of the immune system.
\n \n\n \n \n\n \n\n \n \n \n \n NDM-CGHR\n \n \n\n \n\n\n
\n \n\n \n15 July 2020
\n \n \n \nThe global research community asks for the right research in the right places for COVID-19. The Global Health Network, the African Academy of Sciences and UK Collaborative on Development Research release a report in Nature that calls for the use of research evidence on the optimal implementation of public health interventions for COVID-19 in varied global settings.
\n \n\n \n \n\n \n\n \n \n \n \n NDM-CGHR\n \n \n\n \n\n\n
\n \n\n \n9 July 2020
\n \n \n \nA major UK research study into the long-term health impacts of COVID-19 on hospitalised patients, involving researchers from the University of Liverpool, has been launched.
\n \n\n \n \n\n \n\n \n \n \n \n KWTRP\n \n \n \n \n NDM-CGHR\n \n \n\n \n\n\n
\n \n\n \n6 July 2020
\n \n \n \nOxford University\u2019s LIFE project has launched a new set of app-based training scenarios that help healthcare workers in Africa safely manage and treat cases of children with suspected COVID-19
\n \n\n \n \n\n \n\n \n \n \n \n OUCRU\n \n \n\n \n\n\n
\n \n\n \n3 July 2020
\n \n \n \nDr Le Van Tan in OUCRU, in collaboration with the Hospital for Tropical Diseases and the Department of Health, has shown that it is common for people who are infected with the virus that causes COVID-19 (SARS-CoV-2) to have no symptoms whatsoever. By testing quarantined people in Vietnam, his team was able to detect asymptomatic individuals. The virus disappeared faster from the bodies of the asymptomatic carriers than from that of symptomatic individuals, but it appeared that some of them still managed to pass the infection on to others.
\n \n\n \n \n\n \n\n \n \n \n \n NDM-CGHR\n \n \n\n \n\n\n
\n \n\n \n3 July 2020
\n \n \n \nThe European Commission has granted Marketing Authorisation to Janssen for a new Ebola vaccine, developed in partnership with the University of Oxford. The Ebola vaccine has already been deployed in the North Kivu region of the Democratic Republic of the Congo (DRC), following recommendation from the WHO\u2019s Strategic Advisory Group of Experts (SAGE), and in Rwanda \u2013 following conditional approval in 2019 under an \u2018exceptional emergency\u2019 \u2013 as part of outbreak containment efforts in the region.
\n \n\n \n \n\n \n\n \n \n \n \n NDM-CGHR\n \n \n\n \n\n\n
\n \n\n \n30 June 2020
\n \n \n \nThe RECOVERY trial was established in March as a randomised clinical trial to test a range of potential treatments for COVID-19, including lopinavir-ritonavir, an antiviral treatment commonly used to treat HIV. There was no significant difference in the primary endpoint of 28-day mortality, and the results were consistent in different subgroups of patients. There was also no evidence of beneficial effects on the risk of progression to mechanical ventilation or length of hospital stay. The trial Steering Committee concluded that there is no beneficial effect of lopinavir-ritonavir in patients hospitalised with COVID-19 and closed that treatment arm.
\n \n\n \n \n\n \n\n \n \n \n \n MORU\n \n \n\n \n\n\n
\n \n\n \n30 June 2020
\n \n \n \nThe UK regulator MHRA announced on 26 June that it would again permit recruitment to the COPCOV COVID-19 prevention clinical trial. The MHRA decision came 5 weeks after it reacted immediately to the now-discredited paper published in The Lancet suggesting harms with hydroxychloroquine, and paused recruitment of UK participants. But The Lancet paper was based on fabricated data and was swiftly retracted. After this interruption, recruitment around the globe to COPCOV can now resume.
\n \n\n \n \n\n \n\n \n \n \n \n NDM-CGHR\n \n \n\n \n\n\n
\n \n\n \n16 June 2020
\n \n \n \nThe RECOVERY trial tests a range of potential treatments for COVID-19, including low-dose dexamethasone (a steroid treatment). Patients were randomised to receive dexamethasone 6 mg once per day for ten days and were compared with patients receiving usual care alone. Dexamethasone reduced deaths by one-third in ventilated patients and by one-fifth in other patients receiving oxygen only; there was no benefit among those patients who did not require respiratory support. Based on these results, 1 death would be prevented by treatment of around 8 ventilated patients or around 25 patients requiring oxygen alone.
\n \n\n \n \n\n \n\n \n \n \n \n NDM-CGHR\n \n \n\n \n\n\n
\n \n\n \n5 June 2020
\n \n \n \nA new statement has been released from Professor Peter Horby and Professor Martin Landray, Chief Investigators of the RECOVERY Trial. RECOVERY was established in March as a randomised clinical trial to test a range of potential drugs for COVID-19, including hydroxycholoroquine. The trial has proceeded at unprecedented speed, enrolling over 11,000 patients from 175 NHS hospitals in the UK. The chief investigators have concluded that there is no beneficial effect of hydroxychloroquine in patients hospitalised with COVID-19.
\n \n\n \n \n\n \n\n \n \n \n \n NDM-CGHR\n \n \n\n \n\n\n
\n \n\n \n20 May 2020
\n \n \n \nThe COVID-19 pandemic has seen some extraordinary medical feats and achievements, which are being rightly celebrated. Researchers at Oxford University have been at the forefront of global efforts, including the first human trials of a COVID-19 vaccine, and the world\u2019s biggest trial of potential COVID-19 treatments, RECOVERY.
\n \n\n \n \n\n \n\n \n \n \n \n NDM-CGHR\n \n \n\n \n\n\n
\n \n\n \n30 April 2020
\n \n \n \nThe results of a placebo-controlled randomised trial of remdesivir in COVID-19 patients have been published in the Lancet. Supported by the ISARIC Support Centre, scientists in China launched a trial of remdesivir in patients hospitalised with COVID-19. The results found no clinical benefit from use of the drug; however, while not statistically significant, the time to clinical improvement and duration of invasive mechanical ventilation were shorter in people treated with remdesivir.
\n \n\n \n \n\n \n\n \n \n \n \n MORU\n \n \n\n \n\n\n
\n \n\n \n29 April 2020
\n \n \n \nThe Epidemiology Department of MORU and National Malaria Control Programme, Cambodia (CNM) have begun to implement a study to assess the efficacy of prophylaxis with artemether-lumefantrine (PAL) against forest malaria in Siem Pang District, north-eastern Cambodia bordering Laos.
\n \n\n \n \n\n \n\n \n \n \n \n NDM-CGHR\n \n \n\n \n\n\n
\n \n\n \n27 April 2020
\n \n \n \nThe International Severe Acute Respiratory and Emerging Infections Consortium (ISARIC) is producing a weekly report using clinical data from its COVID-19 database. To date, this includes data from 19,809 individuals from 244 sites across 25 countries.
\n \n\n \n \n\n \n\n \n \n \n \n NDM-CGHR\n \n \n\n \n\n\n
\n \n\n \n24 April 2020
\n \n \n \nA site team in Malawi used the WWARN Malaria Clinical Trials Toolkit for their antimalarial-antiretroviral drug-drug interaction trial with pregnant women. Clifford Banda and his staff used the CDISC-compliant WWARN REDCap data base template as the basis for their data collection and capture, and used or adapted the many WWARN standard operating procedures and their forms for various administrative, clinical, investigational product, quality, data management and safety aspects of their planned work.
\n \n\n \n \n\n \n\n \n \n \n \n NDM-CGHR\n \n \n\n \n\n\n
\n \n\n \n17 April 2020
\n \n \n \nThe UK government is funding 21 new novel coronavirus research studies, including a project led by Professor Trudie Lang. Research must be undertaken everywhere across the globe during this pandemic. Access and ability to undertake research should be equitable, and this research project, working through The Global Health Network, aims to support healthcare teams in low-resource settings. This is a University of Oxford led programme aiming to enable more and better research in diseases, communities and settings where evidence is lacking.
\n \n\n \n \n\n \n\n \n \n \n \n NDM-CGHR\n \n \n\n \n\n\n
\n \n\n \n6 April 2020
\n \n \n \nThe world\u2019s largest randomised clinical trial of potential coronavirus treatments is well underway in the UK as part of the race to find a treatment. A number of promising treatments are being tested and, if the science supports it, will be given to NHS patients as quickly as possible. Definitive results on whether the treatments are safe and effective are expected within months and, if positive, they could potentially benefit hundreds of thousands of people worldwide. Almost 1,000 patients from 132 different hospitals have been recruited in just 15 days and thousands more are expected to join the Randomised Evaluation of COV-id19 thERapY (RECOVERY) trial in the coming weeks, making it the largest randomised controlled trial of potential COVID-19 treatments in the world.
\n \n\n \n \n\n \n\n \n \n \n \n MORU\n \n \n\n \n\n\n
\n \n\n \n30 March 2020
\n \n \n \nResearchers at MORU and two institutions in the US (University of Washington and La Jolla Institute for Immunology) receive grants from the COVID-19 Therapeutics Accelerator, a large-scale initiative launched by the Bill & Melinda Gates Foundation, Wellcome, and Mastercard to speed the development of and access to therapies for COVID-19.
\n \n\n \n \n